| Detection of circulating tumor DNA in early-and late-stage human malignancies C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ... Science translational medicine 6 (224), 224ra24-224ra24, 2014 | 4167 | 2014 |
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 2465 | 2010 |
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer F Di Nicolantonio, M Martini, F Molinari, A Sartore Bianchi, S Arena, ... Journal of clinical oncology 26 (35), 5705-5712, 2008 | 2094 | 2008 |
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ... Nature 486 (7404), 532-536, 2012 | 1892 | 2012 |
| Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study M Moroni, S Veronese, S Benvenuti, G Marrapese, A Sartore-Bianchi, ... The lancet oncology 6 (5), 279-286, 2005 | 1156 | 2005 |
| Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti–epidermal growth factor receptor antibody therapies S Benvenuti, A Sartore-Bianchi, F Di Nicolantonio, C Zanon, M Moroni, ... Cancer research 67 (6), 2643-2648, 2007 | 1040 | 2007 |
| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ... Nature medicine 21 (7), 795-801, 2015 | 1007 | 2015 |
| A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal CancerHER2 … A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ... Cancer discovery 1 (6), 508-523, 2011 | 934 | 2011 |
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies A Sartore-Bianchi, M Martini, F Molinari, S Veronese, M Nichelatti, ... Cancer research 69 (5), 1851-1857, 2009 | 899 | 2009 |
| Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ... Jama 304 (16), 1812-1820, 2010 | 849 | 2010 |
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016 | 825 | 2016 |
| Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1 … A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Cancer discovery 7 (4), 400-409, 2017 | 692 | 2017 |
| Biomarkers predicting clinical outcome of epidermal growth factor receptor–targeted therapy in metastatic colorectal cancer S Siena, A Sartore-Bianchi, F Di Nicolantonio, J Balfour, A Bardelli Journal of the National Cancer Institute 101 (19), 1308-1324, 2009 | 691 | 2009 |
| Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ... Cancer discovery 3 (6), 658-673, 2013 | 652 | 2013 |
| NTRK gene fusions as novel targets of cancer therapy across multiple tumour types A Amatu, A Sartore-Bianchi, S Siena ESMO open 1 (2), e000023, 2016 | 486 | 2016 |
| Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth G Germano, S Lamba, G Rospo, L Barault, A Magrì, F Maione, M Russo, ... Nature 552 (7683), 116-120, 2017 | 484 | 2017 |
| Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution S Misale, F Di Nicolantonio, A Sartore-Bianchi, S Siena, A Bardelli Cancer discovery 4 (11), 1269-1280, 2014 | 452 | 2014 |
| The genomic landscape of response to EGFR blockade in colorectal cancer A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou, B Lupo, M Sausen, ... Nature 526 (7572), 263-267, 2015 | 422 | 2015 |
| Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab A Sartore-Bianchi, M Moroni, S Veronese, C Carnaghi, E Bajetta, G Luppi, ... Journal of Clinical Oncology 25 (22), 3238-3245, 2007 | 391 | 2007 |
| Early‐onset colorectal cancer in young individuals G Mauri, A Sartore‐Bianchi, AG Russo, S Marsoni, A Bardelli, S Siena Molecular oncology 13 (2), 109-131, 2019 | 370 | 2019 |
Salvatore SienaUniversità degli Studi di Milano, Dipartimento di Oncologia, Ospedale Niguarda, Milano, ItalyZweryfikowany adres z unimi.it
